Insider Trading Alert - ROK, BSX And ABMD Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 19, 2015, 105 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,088.06 to $96,569,200.00.

Highlighted Stocks Traded by Insiders:

Rockwell Automation (ROK) - FREE Research Report

Nosbusch Keith D, who is Chairman, President and CEO at Rockwell Automation, sold 20,000 shares at $125.21 on May 19, 2015. Following this transaction, the Chairman, President and CEO owned 417,721 shares meaning that the stake was reduced by 4.57% with the 20,000-share transaction.

The shares most recently traded at $124.75, down $0.46, or 0.37% since the insider transaction. Historical insider transactions for Rockwell Automation go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 97,627
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 104,427
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 111,648

The average volume for Rockwell Automation has been 1.1 million shares per day over the past 30 days. Rockwell Automation has a market cap of $16.8 billion and is part of the industrial goods sector and industrial industry. Shares are up 12.42% year-to-date as of the close of trading on Tuesday.

Rockwell Automation, Inc. provides industrial automation power, control, and information solutions. The company operates through two segments, Architecture & Software and Control Products & Solutions. The stock currently has a dividend yield of 2.08%. The company has a P/E ratio of 19.9. Currently, there are 7 analysts who rate Rockwell Automation a buy, 2 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ROK - FREE

TheStreet Quant Ratings rates Rockwell Automation as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins, good cash flow from operations and growth in earnings per share. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Rockwell Automation Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Boston Scientific (BSX) - FREE Research Report

Johnson Kristina M, who is Director at Boston Scientific, sold 16,301 shares at $18.10 on May 19, 2015. Following this transaction, the Director owned 0 shares meaning that the stake was reduced by 100% with the 16,301-share transaction.

Mario Ernest, who is Director at Boston Scientific, sold 50,000 shares at $18.09 on May 19, 2015. Following this transaction, the Director owned 211,032 shares meaning that the stake was reduced by 19.15% with the 50,000-share transaction.

The shares most recently traded at $18.08, down $0.01, or 0.07% since the insider transaction. Historical insider transactions for Boston Scientific go as follows:

  • 4-Week # shares bought: 11,700
  • 4-Week # shares sold: 27,964
  • 12-Week # shares bought: 11,700
  • 12-Week # shares sold: 121,877
  • 24-Week # shares bought: 11,700
  • 24-Week # shares sold: 273,385

The average volume for Boston Scientific has been 10.8 million shares per day over the past 30 days. Boston Scientific has a market cap of $24.2 billion and is part of the health care sector and health services industry. Shares are up 36.75% year-to-date as of the close of trading on Tuesday.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. Currently, there are 14 analysts who rate Boston Scientific a buy, 1 analyst rates it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BSX - FREE

TheStreet Quant Ratings rates Boston Scientific as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Boston Scientific Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Abiomed (ABMD) - FREE Research Report

Bolt William J, who is SVP, QA and Regulatory Affairs at Abiomed, sold 4,309 shares at $67.88 on May 19, 2015. Following this transaction, the SVP, QA and Regulatory Affairs owned 101,972 shares meaning that the stake was reduced by 4.05% with the 4,309-share transaction.

Minogue Michael R, who is President, CEO, Chairman at Abiomed, sold 19,683 shares at $67.22 on May 19, 2015. Following this transaction, the President, CEO, Chairman owned 324,789 shares meaning that the stake was reduced by 5.71% with the 19,683-share transaction.

Bowen Robert, who is Chief Financial Officer at Abiomed, sold 6,222 shares at $67.72 on May 19, 2015. Following this transaction, the Chief Financial Officer owned 76,265 shares meaning that the stake was reduced by 7.54% with the 6,222-share transaction.

Greenfield Andrew J, who is VP Healthcare Solutions at Abiomed, sold 10,654 shares at $67.34 on May 19, 2015. Following this transaction, the VP Healthcare Solutions owned 60,584 shares meaning that the stake was reduced by 14.96% with the 10,654-share transaction.

Weber David M, who is Chief Operating Officer at Abiomed, sold 5,112 shares at $67.22 on May 19, 2015. Following this transaction, the Chief Operating Officer owned 135,618 shares meaning that the stake was reduced by 3.63% with the 5,112-share transaction.

Howley Michael G, who is VP, Global Sales & Marketing at Abiomed, sold 4,859 shares at $67.22 on May 19, 2015. Following this transaction, the VP, Global Sales & Marketing owned 77,889 shares meaning that the stake was reduced by 5.87% with the 4,859-share transaction.

The shares most recently traded at $66.59, down $0.63, or 0.95% since the insider transaction. Historical insider transactions for Abiomed go as follows:

  • 4-Week # shares sold: 13,335
  • 12-Week # shares sold: 13,335
  • 24-Week # shares sold: 27,335

The average volume for Abiomed has been 588,800 shares per day over the past 30 days. Abiomed has a market cap of $2.8 billion and is part of the health care sector and health services industry. Shares are up 78.69% year-to-date as of the close of trading on Tuesday.

ABIOMED, Inc. provides medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. The company has a P/E ratio of 25.9. Currently, there are 4 analysts who rate Abiomed a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ABMD - FREE

TheStreet Quant Ratings rates Abiomed as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Abiomed Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Rockwell Set to Move Higher

Rockwell Set to Move Higher

There Is Good and a Lot of Bad in General Electric Earnings

There Is Good and a Lot of Bad in General Electric Earnings

Can Industrial Stocks Keep Rallying?: Cramer's 'Off the Charts'

Can Industrial Stocks Keep Rallying?: Cramer's 'Off the Charts'

Tax Reform Makes These 21 Undervalued Industrial Stocks Must Buys for 2018

Tax Reform Makes These 21 Undervalued Industrial Stocks Must Buys for 2018

Wall Street Reaches Records on GOP Tax Progress

Wall Street Reaches Records on GOP Tax Progress